UY38431A - Formulación basada en ciclodextrina de un inhibidor de bcl-2 - Google Patents
Formulación basada en ciclodextrina de un inhibidor de bcl-2Info
- Publication number
- UY38431A UY38431A UY0001038431A UY38431A UY38431A UY 38431 A UY38431 A UY 38431A UY 0001038431 A UY0001038431 A UY 0001038431A UY 38431 A UY38431 A UY 38431A UY 38431 A UY38431 A UY 38431A
- Authority
- UY
- Uruguay
- Prior art keywords
- cyclodextrin
- pharmaceutical composition
- relates
- bcl
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
La invención se refiere a una composición farmacéutica que comprende 5-(5-cloro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroisoquinolin-2(1H)-il]carbonil}fenil)-N-(5-ciano-1,2-dimetil-1H-pirrol-3-il)-N-(4-hidroxifenil)-1,2-dimetil-1H-pirrol-3-carboxamida, referida en la presente memoria como ‘Compuesto A’, o una sal farmacéuticamente aceptable de la misma, y una ciclodextrina. Más específicamente, la invención se refiere a una composición farmacéutica sólida que comprende el Compuesto A y una ciclodextrina, y una composición farmacéutica para administración parenteral preparada disolviendo esta composición farmacéutica sólida. Además, la invención se refiere al uso de dichas composiciones para el tratamiento del cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862753164P | 2018-10-31 | 2018-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY38431A true UY38431A (es) | 2020-05-29 |
Family
ID=68536777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001038431A UY38431A (es) | 2018-10-31 | 2019-10-29 | Formulación basada en ciclodextrina de un inhibidor de bcl-2 |
Country Status (25)
Country | Link |
---|---|
US (1) | US20210353633A1 (es) |
EP (1) | EP3873529A1 (es) |
JP (1) | JP2022506069A (es) |
KR (1) | KR20210102886A (es) |
CN (1) | CN112912108A (es) |
AR (1) | AR116922A1 (es) |
AU (1) | AU2019373373B2 (es) |
BR (1) | BR112021007987A2 (es) |
CA (1) | CA3117511A1 (es) |
CL (1) | CL2021001018A1 (es) |
CO (1) | CO2021005221A2 (es) |
CR (1) | CR20210210A (es) |
DO (1) | DOP2021000073A (es) |
EA (1) | EA202191144A1 (es) |
GE (1) | GEP20237580B (es) |
IL (1) | IL282688A (es) |
JO (1) | JOP20210079A1 (es) |
MX (1) | MX2021004864A (es) |
NI (1) | NI202100031A (es) |
PE (1) | PE20211738A1 (es) |
PH (1) | PH12021550878A1 (es) |
SG (1) | SG11202103965TA (es) |
TW (1) | TWI738100B (es) |
UY (1) | UY38431A (es) |
WO (1) | WO2020089286A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023537290A (ja) | 2020-07-31 | 2023-08-31 | レ ラボラトワール セルヴィエ | 癌を処置するためのBcl-2阻害薬と低メチル化剤との組合せ、その使用及び医薬組成物 |
WO2022090443A1 (en) | 2020-10-30 | 2022-05-05 | Les Laboratoires Servier | Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor |
CN116997544A (zh) | 2021-03-24 | 2023-11-03 | 法国施维雅药厂 | 用于合成5-{5-氯-2-[(3s)-3-[(吗啉-4-基)甲基]-3,4-二氢异喹啉-2(1h)-羰基]苯基}-1,2-二甲基-1h-吡咯-3-甲酸衍生物的新方法及其在生产药物化合物中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5774796A (en) * | 1995-06-13 | 1997-01-09 | Dyer, Alison Margaret | Pharmaceutical compositions containing lornoxicam and cyclod extrin |
JP2003321364A (ja) * | 2002-05-07 | 2003-11-11 | Eisai Co Ltd | シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物 |
WO2014108918A2 (en) * | 2013-01-08 | 2014-07-17 | Mylan Laboratories Limited | An injectable antifungal formulation |
FR3008975A1 (fr) | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US20200054639A1 (en) * | 2016-10-31 | 2020-02-20 | Oregon Health & Science University | Combinations of agents to treat hematological malignancies |
-
2019
- 2019-10-29 UY UY0001038431A patent/UY38431A/es unknown
- 2019-10-30 MX MX2021004864A patent/MX2021004864A/es unknown
- 2019-10-30 TW TW108139349A patent/TWI738100B/zh active
- 2019-10-30 JP JP2021523227A patent/JP2022506069A/ja active Pending
- 2019-10-30 AR ARP190103144A patent/AR116922A1/es unknown
- 2019-10-30 EP EP19801728.7A patent/EP3873529A1/en active Pending
- 2019-10-30 EA EA202191144A patent/EA202191144A1/ru unknown
- 2019-10-30 BR BR112021007987-4A patent/BR112021007987A2/pt unknown
- 2019-10-30 CA CA3117511A patent/CA3117511A1/en active Pending
- 2019-10-30 CN CN201980070474.4A patent/CN112912108A/zh active Pending
- 2019-10-30 KR KR1020217016354A patent/KR20210102886A/ko active Search and Examination
- 2019-10-30 CR CR20210210A patent/CR20210210A/es unknown
- 2019-10-30 SG SG11202103965TA patent/SG11202103965TA/en unknown
- 2019-10-30 US US17/288,721 patent/US20210353633A1/en active Pending
- 2019-10-30 GE GEAP201915618A patent/GEP20237580B/en unknown
- 2019-10-30 WO PCT/EP2019/079644 patent/WO2020089286A1/en active Application Filing
- 2019-10-30 PE PE2021000642A patent/PE20211738A1/es unknown
- 2019-10-30 AU AU2019373373A patent/AU2019373373B2/en active Active
- 2019-10-30 JO JOP/2021/0079A patent/JOP20210079A1/ar unknown
-
2021
- 2021-04-20 PH PH12021550878A patent/PH12021550878A1/en unknown
- 2021-04-21 CL CL2021001018A patent/CL2021001018A1/es unknown
- 2021-04-21 DO DO2021000073A patent/DOP2021000073A/es unknown
- 2021-04-23 CO CONC2021/0005221A patent/CO2021005221A2/es unknown
- 2021-04-27 IL IL282688A patent/IL282688A/en unknown
- 2021-04-29 NI NI202100031A patent/NI202100031A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2019373373A1 (en) | 2021-05-20 |
BR112021007987A2 (pt) | 2021-08-03 |
AU2019373373B2 (en) | 2023-09-28 |
KR20210102886A (ko) | 2021-08-20 |
CO2021005221A2 (es) | 2021-07-19 |
PE20211738A1 (es) | 2021-09-06 |
JOP20210079A1 (ar) | 2023-01-30 |
SG11202103965TA (en) | 2021-05-28 |
CL2021001018A1 (es) | 2021-11-26 |
AR116922A1 (es) | 2021-06-30 |
CR20210210A (es) | 2021-05-25 |
GEP20237580B (en) | 2023-12-25 |
DOP2021000073A (es) | 2021-11-15 |
TWI738100B (zh) | 2021-09-01 |
IL282688A (en) | 2021-06-30 |
CA3117511A1 (en) | 2020-05-07 |
EA202191144A1 (ru) | 2021-09-27 |
NI202100031A (es) | 2021-08-24 |
JP2022506069A (ja) | 2022-01-17 |
TW202031295A (zh) | 2020-09-01 |
WO2020089286A1 (en) | 2020-05-07 |
CN112912108A (zh) | 2021-06-04 |
MX2021004864A (es) | 2021-08-11 |
EP3873529A1 (en) | 2021-09-08 |
US20210353633A1 (en) | 2021-11-18 |
PH12021550878A1 (en) | 2021-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021001018A1 (es) | Formulación basada en ciclodextrina de un inhibidor de bcl-2 | |
UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
BR112016011949A2 (pt) | Composto, composição farmacêutica, e, uso dos mesmos | |
JP2017008088A5 (es) | ||
UY37952A (es) | Formulaciones de un inhibidor de la quinasa trk macrocíclica | |
HUP0303271A2 (hu) | Rapamycin felhasználása rák kezelésére alkalmas gyógyszerkészítmény elõállítására | |
TR201802944T4 (tr) | İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇ | |
EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
BR112012033077B8 (pt) | Composição farmacêutica para administração intravenosa, uso de uma composição farmacêutica, e, kit | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
AR048336A1 (es) | Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
BRPI0816798A2 (pt) | composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação | |
CO6280574A2 (es) | Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia | |
BRPI0906444A8 (pt) | compostos de 4-piridinona e seu uso para câncer | |
CL2021001629A1 (es) | Compuestos de halo-alilamina y uso de los mismos | |
WO2012168885A9 (en) | Bisacodyl and its analogues as drugs for use in the treatment of cancer | |
Mandegary et al. | Indomethacin-enhanced anticancer effect of arsenic trioxide in A549 cell line: involvement of apoptosis and phospho-ERK and p38 MAPK pathways | |
BR112022002392A2 (pt) | Formas em estado sólido de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetra-hidronaftalen-2-il)amino)-n-(1-(2-metil-1)-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida e seus usos | |
AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
JP2018506533A5 (es) | ||
UY30126A1 (es) | Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones | |
SV2011004017A (es) | Tratamiento del cancer de pancreas | |
BRPI0418743A (pt) | métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit | |
BR112022019864A2 (pt) | Composto de oxofenilarsina deuterada e uso do mesmo |